Promisingly, three drugs targeting H3K4 demethylases have reached clinical trials: KDM1A inhibitor ORY-1001 for acute myeloid leukemia and small cell lung cancer, KDM1A inhibitor GSK2879552 for myelodysplastic syndromes, and KDM5 inhibitor GS-5801 for chronic hepatitis B infection. The gene discussed is KDM1A; the disease is chronic hepatitis B virus infection.